Kintara Therapeutics, Inc. - FORM 8-K - EX-10.3 - AMENDMENT NO. 1, DATED FEBRUARY 21, 2017 BETWEEN DELMAR PHARMACEUTICALS, INC. AN - April 13, 2017

Attached files

file filename
8-K - CURRENT REPORT - Kintara Therapeutics, Inc.f8k0417_delmarpharma.htm
EX-99.2 - PRESS RELEASE OF DELMAR PHARMACEUTICALS, INC. ISSUED APRIL 13, 2017 - Kintara Therapeutics, Inc.f8k0417ex99ii_delmarpharma.htm
EX-99.1 - PRESS RELEASE OF DELMAR PHARMACEUTICALS, INC. ISSUED APRIL 12, 2017 - Kintara Therapeutics, Inc.f8k0417ex99i_delmarpharma.htm
EX-10.4 - AMENDMENT NO. 2, DATED APRIL 4, 2017 BETWEEN DELMAR PHARMACEUTICALS, INC. AND RO - Kintara Therapeutics, Inc.f8k0417ex10iv_delmarpharma.htm
EX-10.2 - ENGAGEMENT LETTER, DATED JANUARY 24, 2017 BETWEEN DELMAR PHARMACEUTICALS, INC. A - Kintara Therapeutics, Inc.f8k0417ex10ii_delmarpharma.htm
EX-10.1 - FORM OF SECURITIES PURCHASE AGREEMENT, DATED AS OF APRIL 12, 2017 AMONG DELMAR P - Kintara Therapeutics, Inc.f8k0417ex10i_delmarpharma.htm
EX-5.1 - OPINION OF FENNEMORE CRAIG, P.C. - Kintara Therapeutics, Inc.f8k0417ex5i_delmarpharma.htm
EX-4.1 - FORM OF COMMON STOCK PURCHASE WARRANT - Kintara Therapeutics, Inc.f8k0417ex4i_delmarpharma.htm

Exhibit 10.3

 

February 21, 2017

 

STRICTLY CONFIDENTIAL

 

Jeffrey Bacha

Chairman & CEO

DelMar Pharmaceuticals, Inc.

Suite 720 - 999 West Broadway

Vancouver, British Columbia

Canada V5Z 1K5

 

Dear Mr. Bacha:

 

This letter shall serve as an amendment (the “Amendment”) to that certain engagement letter (the “Original Letter”), dated as of January 24, 2017, by and between DelMar Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). Defined terms used herein and not otherwise defined herein shall have the meaning ascribed to them in the Original Letter.

 

Wainwritght and the Company hereby mutually agree to extend the Term of the Original Letter pursuant to Section B. for an additional 30 days.

 

Except as modified by this letter, the terms, provisions and requirements of the Original Letter shall remain the same and in full force and effect in accordance with the terms and provisions thereof.

 

  Very truly yours,
     
  H.C. WAINWRIGHT & CO., LLC
     
  By: /s/ Edward D. Silvera
    Name: Edward D. Silvera
    Title:   COO

 

Accepted and Agreed:
     

DELMAR PHARMACEUTICALS, INC.
     
 By: /s/ Jeffrey A. Bacha  
 Name: Jeffrey A. Bacha
Title Chairman & CEO

Kintara Therapeutics, Inc. Reports